Wednesday, July 8, 2026

Patent intelligence · US

US 11882920

Systems, devices and methods for styling hair

granted A61KA61K2800/43A61K2800/83A61K8/19
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 308
Patent details — US 11882920
Jurisdiction
US
Status
granted
Grant date
Jan 30, 2024
Expiration
Jan 25, 2044
Claims
14
CPC classes
A61K, A61K2800/43, A61K2800/83, A61K8/19
View on Google Patents ↗

Quick answer

US 11882920 (Systems, devices and methods for styling hair) is held by MIRAKEL TECHNOLOGIES, INC.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K2800/43, A61K2800/83, A61K8/19, A61K8/731, A61K8/88

More from MIRAKEL TECHNOLOGIES, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421228

    Naphthyridine derivatives as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12421253

    Tetrahydropyridopyrimidine pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  3. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Expires Sep 11, 2045

    granted
  4. US 12412764

    Substrate-accommodating container

    MIRAIAL CO., LTD. · Expires Sep 4, 2045

    granted
  5. US 12398154

    Azaquinazoline pan-KRas inhibitors

    Mirati Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  6. US 12383503

    Adagrasib solid pharmaceutical compositions

    Mirati Therapeutics, Inc. · Expires Aug 7, 2045

    granted
  7. US 12377101

    Combination therapies

    Mirati Therapeutics, Inc. · Expires Jul 31, 2045

    granted
  8. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 11882920?

US 11882920 (Systems, devices and methods for styling hair) is held by MIRAKEL TECHNOLOGIES, INC.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11882920?

MIRAKEL TECHNOLOGIES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.

When does US 11882920 expire?

Our index shows an expiration date of Jan 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.